Study guide
10.3 Skin Cancer Clinical Assessment & Counseling
ABFM Family Medicine Certification Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making
1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care
2 Chapter 2: Healthcare Systems, Practice Management & Quality
2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination
3 Chapter 3: Ethics, Law, Biostatistics & Health Equity
3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism
4 Chapter 4: Lifestyle Counseling & Behavior Change
4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling
5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention
5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling
6 Chapter 6: Routine Adult Immunizations
6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise
7 Chapter 7: Pediatric Health Maintenance & Surveillance
7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride
8 Chapter 8: Behavioral Health & Safety Screening
8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling
9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic
9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening
10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic
10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling
11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate
11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making
12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception
12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C
13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care
13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam
14 Chapter 14: Emergent Cardiovascular Conditions
14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies
15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises
15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management
16 Chapter 16: Vascular & Thromboembolic Emergencies
16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion
17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness
17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion
18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies
18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies
19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies
19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice
20 Chapter 20: Acute Pulmonary & Airway Emergencies
20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction
21 Chapter 21: Acute Traumatic Injuries & Wound Care
21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites
22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies
22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises
23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies
23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection
24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies
24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis
25 Chapter 25: Hematologic, Urologic & Dental Emergencies
25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma
26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies
26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia
27 Chapter 27: Acute Head, Neck & Neurologic Symptoms
27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring
28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms
28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis
29 Chapter 29: Acute Upper Respiratory Tract Infections
29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion
30 Chapter 30: Acute Lower Respiratory Infections & Cough
30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia
31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions
31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation
32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms
32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation
33 Chapter 33: Acute Upper Gastrointestinal Conditions
33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness
34 Chapter 34: Acute Lower Gastrointestinal Conditions
34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani
35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders
35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes
36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders
36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis
37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions
37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation
38 Chapter 38: Acute Infectious Dermatoses
38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum
39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses
39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma
40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries
40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains
41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries
41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes
42 Chapter 42: Acute Ambulatory Fractures & Dislocations
42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation
43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls
43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients
44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain
44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies
45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions
45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction
46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions
46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation
47 Chapter 47: Acute Women's Health & Early Pregnancy Care
47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder
48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination
48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis
49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections
49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses
50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia
50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT
51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases
51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy
52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD
52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria
53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus
53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance
54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases
54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition
55 Chapter 55: Chronic Endocrine Disorders
55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders
56 Chapter 56: Chronic Kidney Disease & Venous Disorders
56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD
57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases
57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy
58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care
58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders
59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders
59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome
60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders
60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care
61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders
61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness
62 Chapter 62: Chronic Psychiatric Disorders
62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder
63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions
63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating
64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation
64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy
65 Chapter 65: Chronic Dermatologic Conditions
65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus
66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care
66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control
67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit
67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit
10.3 Skin Cancer Clinical Assessment & Counseling
Key Takeaways Explain This Topic AI
The USPSTF concludes that evidence is insufficient (Grade I) to assess the balance of benefits and harms of routine visual skin examination by a clinician for whole-body skin cancer screening in asymptomatic adults.
The USPSTF issues a Grade B recommendation for behavioral counseling to minimize ultraviolet radiation exposure for children, adolescents, and young adults aged 6 months to 24 years with fair skin phenotypes.
Evolution—a documented change in size, shape, color, elevation, or new symptoms—represents the single most sensitive clinical parameter in the ABCDE diagnostic assessment of malignant melanoma.
For any suspicious pigmented lesion concerning for melanoma, the standard diagnostic procedure is a complete, full-thickness excisional biopsy with 1 to 3 mm narrow margins down to subcutaneous fat; superficial shave biopsy is contraindicated because it transects the deep margin and compromises Breslow depth measurement.
Actinic keratoses are UV-induced precancerous keratinocyte dysplasias; isolated lesions respond to liquid nitrogen cryotherapy, whereas extensive field cancerization requires topical 5-fluorouracil (5-FU 5% twice daily for 2 to 4 weeks) or topical imiquimod.
Last updated: September 2026
USPSTF Screening & Behavioral Counseling Recommendations
Cutaneous malignancies represent the most common group of neoplasms diagnosed in the United States, encompassing melanoma and non-melanoma skin cancers (predominantly basal cell carcinoma and squamous cell carcinoma). Primary care clinicians frequently evaluate suspicious lesions and provide preventive skin counseling:
1. Whole-Body Visual Skin Examination: USPSTF Grade I (Insufficient Evidence)
The Recommendation : The USPSTF concludes that the current evidence is insufficient (Grade I) to assess the balance of benefits and harms of routine whole-body visual skin examination conducted by a clinician for skin cancer screening in asymptomatic adults.
Evidence Synthesis : No randomized controlled trials demonstrate that population-level whole-body skin examinations reduce melanoma or non-melanoma skin cancer mortality. Population screening identifies large numbers of early-stage in situ lesions and indolent basal cell carcinomas, raising serious concerns regarding overdiagnosis and downstream surgical complications (wound infection, scarring, cosmetic disfigurement, and patient anxiety) without altering survival.
Crucial Primary Care Practice Distinction : The Grade I recommendation applies strictly to asymptomatic, whole-body population screening . It does not apply to targeted evaluations. Family physicians must perform prompt, rigorous visual skin examinations whenever:
A patient reports a new, changing, symptomatic, or bleeding cutaneous lesion.
An abnormal pigmented or non-pigmented lesion is incidentally visualized during routine care.
Evaluating high-risk cohorts: personal history of melanoma, multiple first-degree relatives with melanoma, dysplastic nevus syndrome (atypical mole syndrome), or chronic immunosuppression (solid organ transplant recipients).
2. Behavioral Counseling for Skin Cancer Prevention: USPSTF Grade B
Ages 6 Months to 24 Years (Fair Skin Types) : The USPSTF issues a Grade B recommendation to counsel children, adolescents, and young adults aged 6 months to 24 years who have fair skin phenotypes regarding minimizing exposure to ultraviolet (UV) radiation.
Target Cohort : Individuals with Fitzpatrick skin types I through III—characterized by pale or fair skin, blue or green eyes, red or blond hair, and a tendency to burn easily and tan poorly.
Core Counseling Elements : Minimizing peak outdoor midday sun exposure (between 10:00 AM and 4:00 PM); wearing sun-protective clothing (broad-brimmed hats, UV-blocking sunglasses, tightly woven long-sleeved garments); seeking shade; applying broad-spectrum, water-resistant sunscreen with a Sun Protection Factor (SPF) of >=30 every 2 hours and after swimming or sweating; and strictly avoiding indoor tanning beds and artificial UV lamps.
Adults Older Than 24 Years : The USPSTF assigns a Grade I (insufficient evidence) recommendation for behavioral skin cancer counseling in adults older than 24, as clinical trials show counseling yields small, inconsistent changes in adult sun protection behaviors without proven reductions in cancer incidence.
Infants Younger Than 6 Months : Due to immature cutaneous epidermal barriers and elevated systemic chemical absorption, chemical sunscreens are not routinely recommended in infants under 6 months of age. Primary prevention relies on keeping infants out of direct sunlight through physical shade, stroller canopies, and protective clothing.
Clinical Assessment of Pigmented Lesions: ABCDE Criteria & Clinical Signs
Accurate clinical assessment differentiates benign melanocytic nevi from deadly cutaneous malignant melanoma:
The ABCDE Criteria
A - Asymmetry : One half of the pigmented lesion does not match the contralateral half along any bisecting axis.
B - Border Irregularity : The margins are notched, scalloped, ragged, jagged, or poorly circumscribed, fading imperceptibly into surrounding normal skin.
C - Color Variegation : Presence of multiple shades within a single lesion, including tan, dark brown, jet black, and occasionally white, red, or slate-blue. White hues reflect areas of spontaneous host immunological regression; blue hues signify melanin localized within the deep reticular dermis (the optical Tyndall effect).
D - Diameter : A diameter >6 mm (approximately the diameter of a standard pencil eraser). Critical Exam Caveat : Up to 30% of melanomas (particularly nodular and superficial spreading variants) measure <6 mm at the time of initial clinical diagnosis; diameter alone should never dissuade clinical biopsy if other atypical features are present.
E - Evolving / Evolution : Any dynamic change over time—including rapid enlargement, alteration in structural shape, darkening or lightening of color, development of new surface contour elevation, or the onset of localized symptoms (pruritus, tenderness, ulceration, or spontaneous bleeding). Evolution is the single most sensitive clinical parameter for the detection of early melanoma!
The "Ugly Duckling" Sign
In any given patient, benign melanocytic nevi tend to share a consistent architectural phenotype (a shared "signature pattern"). The ugly duckling sign denotes a solitary pigmented lesion that deviates markedly from the patient's dominant nevus pattern—differing distinctly in size, color, geometry, or elevation. A discordant "ugly duckling" lesion possesses a high positive predictive value for melanoma and warrants immediate biopsy.
Dermoscopy Fundamentals in Primary Care
Dermoscopy (epiluminescence microscopy using a handheld dermatoscope with 10x magnification and cross-polarized light) substantially improves diagnostic sensitivity and specificity for melanoma compared to naked-eye examination alone. Cardinal dermatoscopic structures suspicious for melanoma include:
Atypical Pigment Network : A broadened, hyperpigmented, irregular reticular network with non-uniform mesh sizes that terminates abruptly at the periphery.
Irregular Streaks & Pseudopods : Asymmetric linear projections or bulbous finger-like extensions along the lesion margin, indicating active radial horizontal growth.
Asymmetric Dots & Globules : Pigment aggregates of variable size and color distributed non-uniformly throughout the lesion.
Blue-White Veil : An irregular, confluent, structureless hazy blue pigmentation with an overlying white ground-glass haze, reflecting orthokeratosis over deep dermal melanin nests.
Atypical Polymorphous Vessels : Irregularly dispersed corkscrew, hairpin, dotted, or linear-irregular vessels reflecting aggressive tumor neo-angiogenesis.
Malignant Melanoma Subtypes & Histopathologic Staging
Melanoma arises from the malignant transformation of neuroectodermally derived melanocytes residing within the basal layer of the epidermis:
Master Comparison of Melanoma Subtypes
Melanoma Subtype Relative Frequency Anatomical Distribution & UV Association Clinical Presentation & Histopathologic Growth Pattern
Superficial Spreading Melanoma ~70% of all melanomas (most common overall) Intermittently sun-exposed skin: trunk in men, lower extremities in women; strong association with blistering childhood sunburns Prolonged horizontal (radial) growth phase within epidermis before invading vertically into dermis; presents as an asymmetric, multicolored macule or plaque with irregular borders
Nodular Melanoma ~15% of all melanomas (second most common) Any anatomical location, including sun-exposed or covered skin; trunk, head, and neck Minimal or absent radial growth phase; rapid vertical growth phase from inception; presents as an aggressive, dark blue-black, brown, or amelanotic (pink/flesh-colored) dome-shaped nodule; responsible for disproportionate melanoma mortality
Lentigo Maligna Melanoma ~5% to 10% of all melanomas Chronically sun-damaged skin of elderly individuals: face, cheeks, nose, forehead, neck, and dorsal forearms Arises from lentigo maligna (in situ melanoma); prolonged radial growth phase lasting years or decades; presents as a large, flat, slowly enlarging, freckle-like tan-brown patch with variegated borders before vertical invasion emerges
Acral Lentiginous Melanoma ~2% to 3% of all melanomas; accounts for 30% to 70% of melanomas in Black, Hispanic, and Asian populations Non-hair-bearing, non-sun-exposed surfaces: palms, soles (plantar surface), and subungual nail beds Zero association with ultraviolet radiation ; presents as an expanding hyperpigmented macule or band; under the nail, presents as longitudinal melanonychia with Hutchinson's sign (pigment extending onto periungual cuticle/nail fold); frequently diagnosed at advanced stages due to clinical neglect
Breslow Depth: The Gold Standard of Prognostic Microstaging
Definition : Breslow depth is measured in millimeters from the top of the epidermal granular layer (or the base of an ulceration) to the deepest invading malignant melanocyte in the dermis or subcutis.
Prognostic Impact : Breslow depth represents the single most powerful, reproducible prognostic factor for localized cutaneous melanoma, directly predicting 5-year survival, metastatic risk, and surgical resection margins.
Surgical Wide Local Excision Margins :
Melanoma in situ : 0.5 cm margin.
T1 (Breslow depth <=1.0 mm) : 1.0 cm margin.
T2 (Breslow depth 1.01 to 2.0 mm) : 1.0 to 2.0 cm margin.
T3/T4 (Breslow depth >2.0 mm) : 2.0 cm margin.
Sentinel Lymph Node Biopsy (SLNB) : Recommended and routinely discussed for all melanomas with a Breslow depth >=0.8 mm (or <0.8 mm with adverse features such as ulceration or high mitotic activity).
- Non-Melanoma Skin Cancers (NMSC)
- Basal Cell Carcinoma (BCC)
Basal cell carcinoma is the most common malignancy in humans, accounting for approximately 80% of all non-melanoma skin cancers. It arises from basaloid keratinocytes within the hair follicle bulge or interfollicular epidermis, driven by genetic mutations in the Hedgehog signaling pathway (specifically PTCH1 gene alterations) induced by intermittent intense UV exposure.
Biological Behavior : Metastatic dissemination is extraordinarily rare (<0.1%), but untreated tumors cause destructive local tissue infiltration ("rodent ulcers"), invading cartilage, bone, and nerves.
Clinical Subtypes :
Nodular BCC (~60%): Translucent, "pearly" pink or flesh-colored papule or nodule with prominent branching (arborizing) telangiectasias, rolled borders, and central ulceration or crusting.
Superficial BCC (~20%): Erythematous, slightly scaly, well-demarcated thin plaque with a delicate, thread-like pearly border; commonly located on the trunk and upper extremities.
Morpheaform / Infiltrative / Sclerosing BCC (~5% to 10%): Indurated, flat or slightly depressed, firm, scar-like white-to-yellow plaque with ill-defined borders; subclinical finger-like extension is notorious; high recurrence rates; absolute indication for Mohs micrographic surgery.
Pigmented BCC : Contains abundant melanin; resembles melanoma clinically, but dermoscopy reveals arborizing telangiectasias and blue-gray ovoid nests.
Squamous Cell Carcinoma (SCC)
Cutaneous squamous cell carcinoma represents the second most common skin cancer (~20% of NMSC), arising from the malignant proliferation of epidermal keratinocytes. It is strongly linked to cumulative lifetime UV radiation exposure.
High-Risk Hosts : Immunosuppressed patients face an alarming 65- to 100-fold increased incidence of cutaneous SCC following solid organ transplantation, with tumors exhibiting rapid, aggressive growth.
Clinical Presentation : Firm, hyperkeratotic, indurated, erythematous papule, plaque, or nodule, frequently with central ulceration, thick adherent scaling, or cutaneous horn. Most common on chronically sun-exposed sites (scalp, face, ears, dorsal hands, lower lip).
High-Risk Features for Metastasis :
Tumor diameter >2 cm.
Anatomical location on the lower lip (vermilion border) , ear, or anogenital region.
Histopathologic thickness >4 mm or invasion into subcutaneous adipose tissue (Clark level IV/V).
Perineural or lymphovascular invasion.
Poorly differentiated histology.
Host immunosuppression.
Metastatic Rate : Cutaneous SCC carries an overall 2% to 5% risk of regional lymph node metastasis, which escalates to 10% to 20% for lesions on the lower lip or ear, and up to 30% in organ transplant recipients.
Bowen's Disease (Squamous Cell Carcinoma in Situ) : Full-thickness epidermal atypia without dermal basement membrane invasion. Presents as a sharply demarcated, slowly expanding, erythematous scaly plaque; frequently misdiagnosed as nummular eczema or plaque psoriasis, but completely fails to respond to topical corticosteroids.
Keratoacanthoma : Rapidly enlarging, crateriform, dome-shaped nodule with a central hyperkeratotic keratin core; biologically regarded as a well-differentiated SCC variant requiring complete surgical excision.
Actinic Keratosis (AK)
Actinic keratosis represents a precancerous intraepithelial neoplasm arising from UV-induced TP53 tumor suppressor mutations in basal keratinocytes.
Clinical Presentation : Ill-defined, rough, gritty, sandpaper-like papules or plaques on an erythematous base located on chronically sun-damaged anatomical sites (balding scalp, face, ears, forearms). Lesions are frequently "better felt than seen" .
Malignant Potential : The transformation rate of an individual AK to invasive SCC is estimated at 0.1% to 1% per year; however, because patients typically exhibit dozens of lesions across sun-exposed fields, cumulative lifetime risk of SCC is substantial.
Therapeutic Modalities :
Lesion-Directed Therapy (Isolated AKs) : Liquid nitrogen cryotherapy (-196°C) utilizing an open spray technique with a 5 to 15 second freeze-thaw cycle.
Field-Directed Therapy (Field Cancerization) : Indicated for multiple contiguous actinic keratoses across an entire anatomical region (e.g., forehead, balding scalp, or forearms):
Topical 5-Fluorouracil (5-FU 5% cream) : Applied twice daily for 2 to 4 weeks. Blocks thymidylate synthase to halt DNA synthesis in rapidly dividing dysplastic cells; induces intense inflammatory erythema, blistering, erosion, and ulceration before complete re-epithelialization.
Topical Imiquimod (3.75% or 5% cream) : Toll-like receptor 7 (TLR7) agonist stimulating localized cell-mediated immune clearance.
Photodynamic Therapy (PDT) : Application of a photosensitizer (5-aminolevulinic acid) followed by target illumination with blue or red light.
Diagnostic Biopsy Techniques & Surgical Stewardship
Selecting the appropriate surgical biopsy modality is paramount in primary care to prevent tumor understaging:
1. Suspicious Pigmented Lesions (Rule Out Melanoma)
Gold-Standard Technique : Complete full-thickness excisional biopsy with 1 to 3 mm narrow normal skin margins , extending down into the subcutaneous fat .
Strict Rule Against Superficial Shave Biopsy : A superficial tangential shave biopsy is strictly contraindicated for suspected melanoma. Shave biopsies slice horizontally through the tumor, transecting the deep margin and depriving the dermatopathologist of the ability to measure the true Breslow depth . Understaging a melanoma by shaving its surface leads to inadequate subsequent surgical re-excision margins, omission of indicated sentinel lymph node biopsy, and compromised patient survival.
Anatomical Exceptions : If a suspicious pigmented lesion is exceptionally large, located on an anatomically constrained site (e.g., facial cosmetic subunit, nasal ala, eyelid), or involves an acral surface, a full-thickness punch biopsy or incisional biopsy taken through the thickest, darkest, most clinically atypical portion is acceptable.
2. Suspected Non-Melanoma Skin Cancer (BCC / SCC)
Deep Saucerization (Deep Shave Biopsy) : Performed using a flexible surgical razor or scalpel, extending into the mid-to-deep reticular dermis beneath the lesion base. Highly appropriate for elevated, exophytic, or nodular BCC and SCC.
Punch Biopsy (3 to 4 mm) : Indicated for flat, ulcerative, sclerosing, or morpheaform lesions to evaluate the depth of dermal invasion.
3. Mohs Micrographic Surgery (MMS)
Mohs micrographic surgery is specialized outpatient surgery involving serial horizontal frozen section margin mapping, achieving 100% margin evaluation and maximum conservation of normal tissue.
Standard Indications for Mohs Surgery :
Tumors located in the facial "H-zone" (mask areas: nose, eyelids, eyebrows, lips, ears, temples) or anogenital region.
Aggressive histologic subtypes: morpheaform / sclerosing / infiltrative BCC , or poorly differentiated SCC.
Cutaneous SCC with perineural invasion .
Recurrent skin cancers following previous surgical excision.
Large tumors (>2 cm on trunk/extremities, >1 cm on face/scalp) or lesions with poorly defined clinical margins.